Wellstat's Chemo Overdose Antidote Vistogard Approved
This article was originally published in Scrip
Executive Summary
Privately held Wellstat Therapeutics Corp. on Dec. 11 won a speedier-than-expected FDA approval for Vistogard (uridine triacetate) as an emergency treatment to counter an overdose of 5-fluorouracil (5-FU) or capecitabine or for use in patients who develop certain severe or life-threatening toxicities within four days of receiving those cancer chemotherapy agents.